300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Music
Wine and Spirits
Art
Manufacturing
FinTech
Real Estate
Finance
Sporting Goods
Digital Media
Franchise
Social Media
Financial Services
Non Profit
Internet
Android
Mobile Advertising
Proptech
Enterprise
Impact
Community
Sustainability
Media (Entertainment)
Hardware
Biotech
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
Ireland
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Azerbaijan
Austria
Bulgaria
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Ecuador
Belize
Algeria
Hungary
Italy
Belarus
Finland
Lithuania
Grenada
Israel
Liechtenstein
Honduras
Iceland
Lebanon
Cambodia
Mongolia
Peru
Slovenia
San Marino
Chile
Ukraine
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Namur Invest, VC Fund

Namur Invest

VC Fund

Namur, Belgium

Namur Invest is a VC fund in Namur focused on Health Care and Medical Device. Namur Invest Group provides companies with financing solutions in various forms adapted to their needs, to strengthen their financial.

Total investments:
8
Last investment:
Lead investor:
25%

Last updated:

Industries Namur Invest invests in

Health CareMedical DeviceAuctionsSoftwareWellness

Stages Namur Invest invests in

Series ASeedGrantFunding RoundPost-IPO Debt

Countries Namur Invest invests in

BelgiumUnited States

Round sizes

Series A $658k–$18M

Round size

Series A
$658k–$18M

Investment Focus

Industry

  • Health Care 3 (38%)
  • Medical Device 2 (25%)
  • Auctions 1 (13%)
  • Software 1 (13%)
  • Wellness 1 (13%)
See all 13 industries →

Stage

  • Series A 3 (38%)
  • Seed 1 (13%)
  • Grant 1 (13%)
  • Funding Round 1 (13%)
  • Post-IPO Debt 1 (13%)
See all 6 stages →

Country

  • Belgium 4 (50%)
  • United States 1 (13%)

Investments

CompanyDescriptionRoundLinks
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. $2.3M / Grant / Mar 31, 2026
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. $29.2M / Sep 25, 2025
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. $18M / Series A / Mar 09, 2023
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. $1.5M / Post-IPO Debt / Aug 03, 2022
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. $7.3M / Seed / Dec 15, 2021
Invineo design and development of a "smart machine" for catering and hospitality professionals. $2.7M / Venture - Series Unknown / Apr 19, 2018
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. $4.4M / Series A / Nov 21, 2013
Auctelia offers industrial companies a simple way to manage efficiently their assets throughout their life cycle.Auctelia currently allows companies and intermediaries to sell and buy industrial assets through an effective online auction process. More than 30,000 members from 30 countries are logged in as buyers and Auctelia already managedsales of over EUR 10 of millions worth in assets. $658K / Series A / Dec 01, 2011

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Music
Wine and Spirits
Art
Manufacturing
FinTech
Real Estate
Finance
Sporting Goods
Digital Media
Franchise
Social Media
Financial Services
Non Profit
Internet
Android
Mobile Advertising
Proptech
Enterprise
Impact
Community
Sustainability
Media (Entertainment)
Hardware
Biotech
Transportation
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
LATAM
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
Ireland
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Azerbaijan
Austria
Bulgaria
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Ecuador
Belize
Algeria
Hungary
Italy
Belarus
Finland
Lithuania
Grenada
Israel
Liechtenstein
Honduras
Iceland
Lebanon
Cambodia
Mongolia
Peru
Slovenia
San Marino
Chile
Ukraine
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Namur Invest invest in?

Namur Invest invests primarily in Health Care, Medical Device and Auctions startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Namur Invest's check size?

Namur Invest typically joins rounds of $658k–$18M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Namur Invest participates in.

When did Namur Invest last invest?

The most recent investment recorded for Namur Invest closed in Mar 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Namur Invest Namur Invest Find emails